StressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study of neurodegenerative diseases, and the University of Luxembourg’s spin-off biotech OrganoTherapeutics, are pleased to announce a new collaboration aimed at furthering Parkinson’s disease research through the study of alpha synuclein pathology in midbrain organoids.
The partnership between StressMarq and OrganoTherapeutics will center on the establishment of a real-time quaking-induced conversion (RT-QuIC) assay for alpha synuclein amplification in organoid models, utilizing StressMarq’s novel portfolio of alpha synuclein monomer, oligomer, and fibril preparations.
Dr. Gemma Gómez Giró, Lead Project Scientist at OrganoTherapeutics, remarks:
“I am excited to start this collaboration with Stressmarq to establish an RT-QuIC assay for alpha-synuclein amplification in our organoid models. This assay has become very relevant for diagnostic purposes in Parkinson’s disease patients, however, it has never been tested in organoids. We believe that the high sensitivity of the assay will allow us to detect alpha-synuclein pathological aggregates in our samples, and will become a primary readout in our drug screenings. The products and expertise from StressMarq will be crucial to guide us into succeeding when implementing this assay”.
Advancing Research on Parkinson’s Disease Alpha-synuclein Pathology in Midbrain Organoids
The collaboration agreement between, StressMarq and OrganoTherapeutics signed in October this year will focus on researching alpha-synuclein, a pivotal protein associated with the development of Parkinson’s disease, within organoids. The partnership brings together OrganoTherapeutics’ specialized expertise in creating accurate human-specific models and StressMarq’s commitment to providing innovative research tools for the research of Parkinson’s disease and other neurodegenerative diseases.
OrganoTherapeutics employs a patient-specific brain organoid model to research Parkinson’s Disease pathology in vitro and develop new therapeutics against the disease progression. StressMarq is dedicated to providing high-quality, innovative products to assist researchers studying Parkinson’s disease and other neurodegenerative diseases. Through the use of proprietary, human-specific, 3D in vitro models, OrganoTherapeutics’ midbrain organoids closely mimic Parkinson’s disease pathology in humans, facilitating unique opportunities for the discovery and development of effective drug candidates in the treatment of Parkinson’s disease.
This partnership’s amalgamation of expertise, innovative products, and accurate disease models can pave the way for more profound insights into Parkinson’s disease and the acceleration in the development of therapeutic interventions.
About StressMarq Biosciences:
Established in 2007, StressMarq Biosciences Inc. is a Canadian-based company that produces exceptional bioreagents and cutting-edge research products for the life sciences and drug discovery research markets. With the breadth and depth of its product portfolio of alpha synuclein, tau, amyloid beta, SOD1 and TTR preparations, StressMarq has established itself as a market leader in the development of advanced neurodegenerative disease research products.
For more information please complete the quick contact form or visit: www.stressmarq.com
OrganoTherapeutics was established in July 2019 as a spin-off biotech from the University of Luxembourg / Luxembourg Centre for Systems Biomedicine. Using a human-specific, personalized, 3D in vitro model, their proprietary midbrain organoids are used to conduct research into the discovery and development of effective drug candidates, with a special interest in targeting neurodegeneration in Parkinson`s disease (PD) patients. OrganoTherapeutics focuses on deep phenotyping and phenotype-based drug screening, as well as artificial intelligence-assisted analysis.
For more information visit: www.organo-therapeutics.com